We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Molecular Diagnostic Test Accurately Predicts Therapy Outcomes in Breast Cancer Patients

By LabMedica International staff writers
Posted on 11 Mar 2024
Print article
Image: RNA Disruption Assay is a cancer diagnostic platform measuring tumor response early in cancer treatment (Photo courtesy of Rna Diagnostics)
Image: RNA Disruption Assay is a cancer diagnostic platform measuring tumor response early in cancer treatment (Photo courtesy of Rna Diagnostics)

Breast cancer remains the leading cause of cancer-related deaths among women. In 2022 alone, it accounted for 2.3 million new cases globally, with 670,000 fatalities. As cancer drug development progresses, the demand for diagnostic tools to optimize these treatments is increasingly needed. Studies, both preclinical and clinical, have shown a significant link between the disruption of ribosomal RNA (rRNA) and the effectiveness of treatment. Notably, a lack of RNA disruption is often tied to a poor response to therapy and a grim prognosis. In primary breast cancer, the disruption of tumor RNA by drugs varies according to each individual's tumor biology, regardless of the cancer subtype. Now, a molecular diagnostics test that evaluates tumor response to anti-cancer drug therapy has the potential utility to enable the timely optimization of cancer treatments.

Developed by Rna Diagnostics (Toronto, Ontario, Canada), the RNA Disruption Assay (RDA) is an innovative test designed to measure the extent of RNA disruption in tumor cells. This test can predict, with remarkable accuracy, the likelihood of complete tumor elimination post-treatment in breast cancer patients undergoing pre-operative chemotherapy. Utilizing RDA testing, oncologists can adapt treatment plans based on an early assessment of a patient’s response, enhancing or reducing treatment as needed. Such timely adjustments in pre-operative treatment could not only minimize the adverse effects of ineffective drugs but also improve patient outcomes by switching to alternative treatment regimens.

Rna Diagnostics has recently released phase 1 results of the BREVITY (Breast Cancer Response Evaluation for Individualized Therapy) clinical trial. This trial, part of an international two-phase study conducted across 55 cancer centers in Canada, the United States, Italy, Germany, France, Spain, and Poland, aims to establish the efficacy of RDA in predicting outcomes from pre-operative chemotherapy. Phase 1 involved 80 patients with stage I, II, or III breast cancer, who underwent pre-operative drug treatment followed by surgical removal of the tumor. These initial results show the assay's strong ability to accurately predict treatment outcomes during the therapy course, enabling oncologists to tailor patient care more effectively.

“Our ultimate goal is to personalize breast cancer treatments. If validated, this test has the potential to accurately predict which treatment will be effective for an individual patient,” said Dr. Foluso Ademuyiwa, Co-Chair of BREVITY Steering Committee.

Related Links:
Rna Diagnostics

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more


view channel
Image: High-speed brightfield scanners offer excellent image quality to aid pathologists\' review of digital slides (Photo courtesy of Roche)

Whole-Slide Imaging System Enables Pathologists to Diagnose Patients Using Digital Images

Digital pathology involves the digitalization of the traditional pathology workflow, starting from slide scanning to visualization, to analysis. Digital pathology is transforming traditional histopathology... Read more


view channel
Image: The global urinalysis market is projected to grow at a CAGR of 9.6% to USD 6.8 billion by 2029 (Photo courtesy of Shutterstock)

Global Urinalysis Market Driven by Technological Advancements in POC Testing

Urinalysis is a practical and efficient technique for analyzing urine samples to detect various infections and chronic diseases such as diabetes, urinary tract infections, and kidney disease.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.